Scientists at The Pirbright Institute have found that deleting a gene of the African swine fever virus (ASFV), a severe and often fatal disease of pigs, reduces its ability to cause infection and protects against a strain of the virus that causes severe disease.
In the study, published in the Journal of Virology, Pirbright scientists deleted an ASFV gene that codes for a protein thought to play a role in suppressing the pig immune system. The resulting modified virus was still able to replicate, but showed a dramatically reduced ability to cause infection, meaning the pigs all survived and only displayed mild clinical signs. After being exposed to the modified strain, the pigs were protected against further infection from a natural strain of ASFV.
Dr Linda Dixon, leader of the ASF group at Pirbright, said: “Now that we have shown the modified virus has the ability to protect pigs against a natural strain, the next steps will be to make more gene deletions that will reduce the clinical signs exhibited by pigs after vaccination.
“We will also be investigating the precise role the protein plays during infection. This information will help us understand how it interacts with the host immune system and if the protein directly prevents immune processes or if it has other roles we haven’t yet identified. Knowing more about the gene and protein will make it easier for us to modify the virus further and create a vaccine that is effective and safe.”
ASF has no vaccine, so the continued efforts of scientists to identify vaccine candidates is essential. The disease is currently spreading further across Europe, with the latest outbreaks described in Romania for the first time. ASF can be very difficult to identify, as it displays similar clinical signs to other pig diseases, with the most harmful strains killing pigs before specific signs become apparent. In regions where infected wild boar are present transmission of ASFV to domestic pigs also complicates the control of the disease.
Current prevention strategies focus around import controls and the education of farm owners on ASF and biosecurity to prevent infection and diagnose rapidly. However, these tools are currently not robust enough to stop the disease spreading across Eastern Europe and Russia, making the need for a vaccine even more pressing.
This Pirbright research has shown that the modified virus could be used as a component of a live attenuated vaccine; a type of vaccine that contains a weakened version of the virus which is able to mimic infection and cause an immune response without causing harm to the animal. These vaccines have recently been reviewed in an article published in Vaccines by the European Union ASF Expert Working Group, which includes Dr. Linda Dixon.
The experts established that live attenuated vaccines are the most promising and best positioned candidates for use in the future against ASF. Although there are still important issues such as safety and effectiveness that need resolving before these vaccines are available commercially, Pirbright scientists anticipate further research on this candidate could lead to the development of an ASF vaccine.
This research was funded by the Biotechnology and Biological Sciences Research Council (BBSRC), grant number (BB/L004267/1) and the European Union’s Seventh Framework Programme (FP7/2007-2013) under Grant Agreement nº 311931, ASFORCE.
About The Pirbright Institute
The Pirbright Institute is a world leading centre of excellence in research and surveillance of virus diseases of farm animals and viruses that spread from animals to humans. Based in the UK and receiving strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), the Institute works to enhance capability to contain, control and eliminate these economically and medically important diseases through highly innovative fundamental and applied bioscience.
With an annual income of nearly £26.1 million from grants and commercial activity, and a total of £5 million strategic investment from BBSRC during 2016-2017, the Institute contributes to global food security and health, improving quality of life for animals and people.
For more information about The Pirbright Institute see: www.pirbright.ac.uk
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by government, BBSRC invested £469 million in world-class bioscience in 2016-17. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
More information about BBSRC, our science and our impact: https://bbsrc.ukri.org/
More information about BBSRC strategically funded institutes: https://bbsrc.ukri.org/research/institutes/strategically-funded-institutes/